*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. The Company's lead product candidate, NL-201, is an interleukin-2 (IL-2)/ interleukin-15 (IL-15) immunotherapy designed to eliminate binding to the alpha subunit of the IL-2 receptor (also known as CD25) while enhancing binding to the beta and gamma subunits. NL-201 is designed to mimic the therapeutic activity of the cytokines IL-2 and IL-15 for the treatment of various types of cancer, including renal cell carcinoma (RCC), melanoma and hematological malignancies. Its Neoleukin platform uses a set of advanced computational algorithms and methods to design functional de novo proteins. NL-201 holds promise in combination with cell therapy to expand and maintain populations of transplanted CAR-T and natural killer (NK) cells.
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
|Date||Event description||Earnings per|
|March 20, 2023||Q4 2022 Earnings Release||-$0.24||-$0.19 to -$0.19||-$0.275|
|November 14, 2022||Q3 2022 Earnings Release||-$0.24||-$0.34 to -$0.26||-$0.28|
|August 9, 2022||Q2 2022 Earnings Release||-$0.28||-$0.33 to -$0.28||-$0.27|
|May 9, 2022||Q1 2022 Earnings Release||-$0.28||-$0.32 to -$0.26||-$0.27|
, , , Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.